Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations: The impact of expensive chemotherapy

Haematologica

Volumn 98, Issue 5, 2013, Pages 753-759

  Tong, Wing H ^a   van der Sluis, Inge M ^a   Alleman, Cathelijne J M ^b   van Litsenburg, Raphaële R L ^c   Kaspers, Gertjan J L ^c   Pieters, Rob ^a   Uyl De Groot, Carin A ^b  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLERGIC REACTION; ARTICLE; CHILD; COST BENEFIT ANALYSIS; DECISION TREE; FEMALE; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; SENSITIVITY ANALYSIS; ADOLESCENT; COMPUTER SIMULATION; ECONOMICS; HEALTH CARE COST; INFANT; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; STATISTICAL MODEL;

ADOLESCENT; ANTINEOPLASTIC AGENTS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DECISION TREES; FEMALE; HEALTH CARE COSTS; HUMANS; INFANT; MALE; MODELS, ECONOMIC; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84877041237     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.073510     Document Type: Article

References (24)

1. Schrappe M, Hunger SP, Pui CH, Saha V, Gaynon PS, Baruchel A, et al. Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med. 2012;366(15):1371-81.
2. Moghrabi A, Levy DE, Asselin B, Barr R, Clavell L, Hurwitz C, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood. 2007;109(3):896-904.
3. Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001;97(5):1211-8.
4. Duval M, Suciu S, Ferster A, Rialland X, Nelken B, Lutz P, et al. Comparison of Escherichia coli-asparaginase with Erwiniaasparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood. 2002;99(8):2734-9.
5. Bussolati O, Belletti S, Uggeri J, Gatti R, Orlandini G, Dall'Asta V, et al. Characterization of apoptotic phenomena induced by treatment with L-asparaginase in NIH3T3 cells. Exp Cell Res. 1995;220 (2):283-91.
6. Rizzari C, Valsecchi MG, Arico M, Conter V, Testi A, Barisone E, et al. Effect of protracted high-dose L-asparaginase given as a second exposure in a Berlin-Frankfurt-Munster-based treatment: results of the randomized 9102 intermediate-risk childhood acute lymphoblastic leukemia study--a report from the Associazione Italiana Ematologia Oncologia Pediatrica. J Clin Oncol. 2001;19(5):1297-303.
7. Pession A, Valsecchi MG, Masera G, Kamps WA, Magyarosy E, Rizzari C, et al. Longterm results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23 (28):7161-7.
8. Amylon MD, Shuster J, Pullen J, Berard C, Link MP, Wharam M, et al. Intensive highdose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia. 1999;13(3):335-42.
9. Pieters R, Hunger SP, Boos J, Rizzari C, Silverman L, Baruchel A, et al. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer. 2011;117(2):238-49.
10. Fu CH, Sakamoto KM. PEG-asparaginase. Expert Opin Pharmacother. 2007;8(12): 1977-84.
11. Kurre HA, Ettinger AG, Veenstra DL, Gaynon PS, Franklin J, Sencer SF, et al. A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli Lasparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children's Cancer Group study (CCG-1962). J Pediatr Hematol. Oncol 2002;24(3):175-81.
12. Peters BG, Goeckner BJ, Ponzillo JJ, Velasquez WS, Wilson AL. Pegaspargase versus asparaginase in adult ALL: a pharmacoeconomic assessment. Formulary. 1995;30(7):388-93.
13. van Litsenburg RR, Uyl-de Groot CA, Raat H, Kaspers GJ, Gemke RJ. Cost-effectiveness of treatment of childhood acute lymphoblastic leukemia with chemotherapy only: the influence of new medication and diagnostic technology. Pediatr Blood. Cancer 2011;57(6):1005-10.
14. van Tilburg CM, Bierings MB, Berbers GA, Wolfs TF, Pieters R, Bloem AC, et al. Impact of treatment reduction for childhood acute lymphoblastic leukemia on serum immunoglobulins and antibodies against vaccine-preventable diseases. Pediatr Blood. Cancer 2012;58(5):701-7.
15. Pieters R, Appel I, Kuehnel HJ, Tetzlaff-Fohr I, Pichlmeier U, van der Vaart I, et al. Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trial. Blood. 2008;112(13):4832-8.
16. Willer A, Gerss J, Konig T, Franke D, Kuhnel HJ, Henze G, et al. Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials. Blood. 2011;118(22):5774-82.
17. Drummond MF. Methods for the economic evaluation of health care programmes Oxford medical publications. 2005; 3rd edition (Oxford: Oxford University Press).
18. Nachman J, Sather HN, Gaynon PS, Lukens JN, Wolff L, Trigg ME. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group. J Clin Oncol. 1997;15(6):2222-30.
19. Abuchowski A, van Es T, Palczuk NC, McCoy JR, Davis FF. Treatment of L5178Y tumor-bearing BDF1 mice with a nonimmunogenic L-glutaminase-L-asparaginase. Cancer Treat Rep. 1979;63(6):1127-32.
20. Yoshimoto T, Nishimura H, Saito Y, Sakurai K, Kamisaki Y, Wada H, et al. Characterization of polyethylene glycolmodified L-asparaginase from Escherichia coli and its application to therapy of leukemia. Jpn J Cancer Res. 1986;77(12): 1264-70.
21. Silverman LB, Supko JG, Stevenson KE, Woodward C, Vrooman LM, Neuberg DS, et al. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood. 2010;115(7): 1351-3.
22. Avramis VI, Sencer S, Periclou AP, Sather H, Bostrom BC, Cohen LJ, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2002;99(6): 1986-94.
23. Schrey D, Speitel K, Lanvers-Kaminsky C, Gerss J, Moricke A, Boos J. Five-year singlecenter study of asparaginase therapy within the ALL-BFM 2000 trial. Pediatr Blood Cancer. 2011;57(3):378-84.
24. Qureshi A, Mitchell C, Richards S, Vora A, Goulden N. Asparaginase-related venous thrombosis in UKALL 2003-re-exposure to asparaginase is feasible and safe. Br J Haematol. 2010;149(3):410-3.